Pfizer Claims Initial Success with Corona Vaccine
After negotiating with the FDA to exclude 32 cases from the interim analysis, the first interim analysis was performed on 62 different cases.
WEB DESK: Pfizer, an international pharmaceutical company, claims that its mRNA vaccine has given clear indications of resistance to Covid-19 during its interim analysis. This analysis was performed on candidates who had the effects of Covid -19.
After negotiating with the FDA to exclude 32 cases from the interim analysis, the first interim analysis was performed on 62 different cases.
UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
— Pfizer Inc. (@pfizer) November 9, 2020
The analysis was divided into two separate sections. The first was those who were vaccinated and the second was those who were given placebo.
Those who were given a placebo showed a 90% improvement in the effectiveness of the vaccine after the second dose.
This means that the required protection is achieved 28 days after the vaccine is given.
The vaccine consisted of two doses.
One Comment